| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Warrant issuance cost | 4,852,292 | - | - | |
| Total other income | 58,124,438 | -382,209 | 959,956 | |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | - | -10,349,410 | |
| Net income (loss) | 45,445,469 | -10,114,270 | -10,349,410 | |
| Earnings per share, diluted, total | -0.21 | -1.09 | -1.12 | |
| Net loss per share, basic | 0.5 | -1.09 | -1.12 | |
| Weighted-average common shares outstanding - basic | 10,660,500 | 9,294,469 | 9,259,192 | |
| Weighted-average common shares outstanding - diluted | 77,863,263 | 9,294,469 | 9,259,192 | |
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)